Downregulation of miR-221/222 sensitizes glioma cells to temozolomide by regulating apoptosis independently of p53 status

Oncology Reports

Volumn 27, Issue 3, 2012, Pages 854-860

  Chen, Lingchao ^a   Zhang, Junxia ^b,c   Han, Lei ^b,c   Zhang, Anling ^b,c   Zhang, Chunzhi ^b,c   Zheng, Yongri ^a   Jiang, Tao ^d   Pu, Peiyu ^b,c   Jiang, Chuanlu ^a   Kang, Chunsheng ^b,c,e  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b TIANJIN MEDICAL UNIVERSITY   (China)

^c BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^d CAPITAL MEDICAL UNIVERSITY   (China)

^e Tianjin Neurological Institute   (China)

Author keywords

Glioblastoma; miR 221 222; p53; Temozolomide

Indexed keywords

APOPTOTIC PROTEASE ACTIVATING FACTOR 1; CASPASE 3; CASPASE 7; CYTOCHROME C; MICRORNA; MICRORNA 221; MICRORNA 222; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53; PUMA PROTEIN; SMALL INTERFERING RNA; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; APOPTOSIS; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; GENE EXPRESSION; GENE SILENCING; GLIOMA CELL; HUMAN; HUMAN CELL; IC 50; OPEN READING FRAME; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROCESSING; PROTEIN TARGETING; UPREGULATION;

APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; APOPTOTIC PROTEASE-ACTIVATING FACTOR 1; BCL-2-ASSOCIATED X PROTEIN; BRAIN NEOPLASMS; CASPASE 3; CYTOCHROMES C; DACARBAZINE; DOWN-REGULATION; GENE KNOCKDOWN TECHNIQUES; GLIOMA; HUMANS; MICRORNAS; MITOCHONDRIA; PROTO-ONCOGENE PROTEINS; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84863046059     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2011.1535     Document Type: Article

References (21)

1. Stupp R, Mason WP, van den Bent MJ, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996, 2005. (Pubitemid 40349501)
2. Gabayan AJ, Green SB, Sanan A, et al: GliaSite brachytherapy for treatment of recurrent malignant gliomas: a retrospective multi-institutional analysis. Neurosurgery 58: 701-709, 2006.
3. Lasky JL III, Choe M and Nakano I: Cancer stem cells in pediatric brain tumors. Curr Stem Cell Res Ther 4: 298-305, 2009.
4. Besch R, Poeck H, Hohenauer T, et al: Proapoptotic signaling induced by RIG-I and MDA-5 results in type I interferon-independent apoptosis in human melanoma cells. J Clin Invest 119: 2399-2411, 2009.
5. Ciafre SA, Galardi S, Mangiola A, et al: Extensive modulation of a set of microRNAs in primary glioblastoma. Biochem Biophys Res Commun 334: 1351-1358, 2009. (Pubitemid 41074723)
6. He H, Jazdzewski K, Li W, et al: The role of microRNA genes in papillary thyroid carcinoma. Proc Natl Acad Sci USA 102: 19075-19080, 2005. (Pubitemid 43049568)
7. Ventura A and Jacks T: MicroRNAs and cancer: short RNAs go a long way. Cell 136: 586-591, 2009.
8. Zhou X, Ren Y, Moore L, et al: Downregulation of miR-21 inhibits EGFR pathway and suppresses the growth of human glioblastoma cells independent of PTEN status. Lab Invest 90: 144-155, 2010.
9. Zhang J, Han L, Ge Y, et al: miR-221/222 promote malignant progression of glioma through activation of the Akt pathway. Int J Oncol 36: 913-920, 2010.
10. Zhang C, Kang C, You Y, et al: Co-suppression of miR-221/222 cluster suppresses human glioma cell growth by targeting p27kip1 in vitro and in vivo. Int J Oncol 34: 1653-1660, 2009.
11. Zhang CZ, Zhang JX, Zhang AL, et al: MiR-221 and miR-222 target PUMA to induce cell survival in glioblastoma. Mol Cancer 9: 229, 2010.
12. Yu J, Zhang L, Hwang PM, Kinzler KW and Vogelstein B: PUMA induces the rapid apoptosis of colorectal cancer cells. Mol Cell 7: 673-682, 2001. (Pubitemid 32706358)
13. Wu M, Jolicoeur N, Li Z, et al: Genetic variations of microRNAs in human cancer and their effects on the expression of miRNAs. Carcinogenesis 29: 1710-1716, 2008.
14. Galardi S, Mercatelli N, Giorda E, et al: miR-221 and miR-222 expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27Kip1. J Biol Chem 282: 23716-23724, 2007. (Pubitemid 47311902)
15. Visone R, Russo L, Pallante P, et al: MicroRNAs (miR)-221 and miR-222, both overexpressed in human thyroid papillary carcinomas, regulate p27Kip1 protein levels and cell cycle. Endocr Relat Cancer 14: 791-798, 2007. (Pubitemid 350074067)
16. Medina R, Zaidi SK, Liu CG, et al: MicroRNAs 221 and 222 bypass quiescence and compromise cell survival. Cancer Res 68: 2773-2780, 2008. (Pubitemid 351556275)
17. Yu J and Zhang L: No PUMA, no death: implications for p53-dependent apoptosis. Cancer Cell 4: 248-249, 2003. (Pubitemid 37329788)
18. Yu J and Zhang L: PUMA, a potent killer with or without p53. Oncogene 27 (Suppl 1): S71-S83, 2008.
19. Ito H, Kanzawa T, Miyoshi T, et al: Therapeutic efficacy of PUMA for malignant glioma cells regardless of p53 status. Hum Gene Ther 16: 685-698, 2005. (Pubitemid 40864269)
20. Hegi ME, Diserens AC, Gorlia T, et al: MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352: 997-1003, 2005. (Pubitemid 40349502)
21. Blough MD, Beauchamp DC, Westgate MR, Kelly JJ and Cairncross JG: Effect of aberrant p53 function on temozolomide sensitivity of glioma cell lines and brain tumor initiating cells from glioblastoma. J Neurooncol 102: 1-7, 2011.